Business Description
Oncopeptides AB
ISIN : SE0009414576
Total Employee Number:
77Compare
Compare
Traded in other countries / regions
ONCO.Sweden0RN4.UKOND.Germany IPO Date
2017-02-28Description
Oncopeptides AB is a Swedish biotech company focusing on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company uses its proprietary Peptide Drug Conjugate platform to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. It is a science-driven biotech company developing targeted therapies for hard-to-treat cancers, combining cutting-edge research, entrepreneurial spirit, and a deep commitment to improving patients' lives. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East, Africa, and elsewhere. The company generates maximum revenue from Germany.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.57 | |||||
Equity-to-Asset | 0.28 | |||||
Debt-to-Equity | 1.7 | |||||
Debt-to-EBITDA | -0.65 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 0.77 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 66.6 | |||||
3-Year EBITDA Growth Rate | 27.7 | |||||
3-Year EPS without NRI Growth Rate | 27.4 | |||||
3-Year FCF Growth Rate | 34.2 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 61.15 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 71.7 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 55.59 | |||||
9-Day RSI | 49.71 | |||||
14-Day RSI | 49.82 | |||||
3-1 Month Momentum % | 16.86 | |||||
6-1 Month Momentum % | -63.87 | |||||
12-1 Month Momentum % | 9.85 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.55 | |||||
Quick Ratio | 4.38 | |||||
Cash Ratio | 3.64 | |||||
Days Inventory | 1005.54 | |||||
Days Sales Outstanding | 137.19 | |||||
Days Payable | 1135.85 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -24.3 | |||||
Shareholder Yield % | -1.11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 96.57 | |||||
Operating Margin % | -242.77 | |||||
Net Margin % | -265.28 | |||||
EBITDA Margin % | -242.77 | |||||
FCF Margin % | -232.48 | |||||
OCF Margin % | -232.48 | |||||
ROA % | -119.07 | |||||
ROIC % | -314.72 | |||||
3-Year ROIIC % | -892.15 | |||||
ROC (Joel Greenblatt) % | -1008.76 | |||||
ROCE % | -153.62 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 5.03 | |||||
PB Ratio | 8.21 | |||||
Price-to-Tangible-Book | 8.28 | |||||
EV-to-EBIT | -2.74 | |||||
EV-to-EBITDA | -2.74 | |||||
EV-to-Revenue | 6.66 | |||||
EV-to-Forward-Revenue | 1.82 | |||||
EV-to-FCF | -2.93 | |||||
Price-to-GF-Value | 0.39 | |||||
| Price-to-Net-Current-Asset-Value | 10.35 | |||||
| Price-to-Net-Cash | 55.22 | |||||
Earnings Yield (Greenblatt) % | -36.45 | |||||
FCF Yield % | -30.76 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Oncopeptides AB Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 83.348 | ||
| EPS (TTM) (kr) | -0.878 | ||
| Beta | 3.808 | ||
| 3-Year Sharpe Ratio | 0.19 | ||
| 3-Year Sortino Ratio | 0.69 | ||
| Volatility % | 333.74 | ||
| 14-Day RSI | 49.82 | ||
| 14-Day ATR (kr) | 0.052313 | ||
| 20-Day SMA (kr) | 1.6639 | ||
| 12-1 Month Momentum % | 9.85 | ||
| 52-Week Range (kr) | 1.267 - 6.122488 | ||
| Shares Outstanding (Mil) | 381.36 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Oncopeptides AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Oncopeptides AB Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 08:00 | In 122 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 | In 121 days | ||
| Second quarter earnings results for 2026 | 2026-08-27 08:00 | In 52 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-27 | In 51 days | ||
| Second quarter earnings results for 2026 | 2026-08-21 08:00 | In 46 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-21 | In 45 days | ||
| General meeting for 2026 | 2026-05-22 10:00 | 1.83 (-8.48%) | ||
| General meeting for 2026 | 2026-05-21 14:00 | 1.97 (+0.79%) | ||
| First quarter earnings conference call for 2026 | 2026-05-13 09:00 | 1.27 (-1.28%) | ||
| First quarter earnings results for 2026 | 2026-05-13 08:00 | 1.27 (-1.28%) |
Show
Entries
Oncopeptides AB Frequently Asked Questions
What is Oncopeptides AB(LTS:0RN4)'s stock price today?
The current price of LTS:0RN4 is kr1.66. The 52 week high of LTS:0RN4 is kr6.12 and 52 week low is kr1.27.
When is next earnings date of Oncopeptides AB(LTS:0RN4)?
The next earnings date of Oncopeptides AB(LTS:0RN4) is .
Does Oncopeptides AB(LTS:0RN4) pay dividends? If so, how much?
Oncopeptides AB(LTS:0RN4) does not pay dividend.
Press Release
Articles on Oncopeptides AB
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers